SoInNuc™
Intelligent Nucleic Acid Drug
Development Platform
SoInNuc™
Intelligent Nucleic Acid Drug Development Platform
Intelligent Design for RNA Therapeutics.
Precision and Specificity from Target to Delivery.
Integrating AI with bioinformatics algorithms, the platform enables target identification and intelligent sequence design for small nucleic acid therapeutics including siRNA and ASO. Powered by a physics engine and RNA language foundation models, the platform predicts silencing efficacy and off-target risks, supporting highly specific optimization and effectively compressing the candidate space to enhance development efficiency.
-
Target Discovery
AI algorithms rapidly screen for potential targets amenable to small nucleic acid intervention, expanding the druggable space. -
Sequence Refinement
RNA language models combined with thermodynamic mechanisms screen the top 0.1% of high-activity sequences from a vast sequence landscape. -
Off-Target Mitigation
Identifies seed-region off-target risks and immunogenicity hotspots, supporting upfront safety design. -
Delivery Assessment
Provides comprehensive delivery solutions including GalNAc and LNP across diverse tissues and organs, such as liver and CNS. -
Dry-Wet Closed Loop
Active learning drives a dry-wet closed loop, reducing blind experimental rounds by over 50%, with daily iterative model updates. -
Patent Positioning
AI-generated de novo sequences supporting differentiated sequence design and intellectual property positioning.
SoInNuc™
Intelligent Nucleic Acid Drug
Development Platform
SoInNuc™
Intelligent Nucleic Acid Drug Development Platform
Intelligent Design for RNA Therapeutics.
Precision and Specificity from Target to Delivery.
Integrating AI with bioinformatics algorithms, the platform enables target identification and intelligent sequence design for small nucleic acid therapeutics including siRNA and ASO. Powered by a physics engine and RNA language foundation models, the platform predicts silencing efficacy and off-target risks, supporting highly specific optimization and effectively compressing the candidate space to enhance development efficiency.
-
Target Discovery
AI algorithms rapidly screen for potential targets amenable to small nucleic acid intervention, expanding the druggable space. -
Sequence Refinement
RNA language models combined with thermodynamic mechanisms screen the top 0.1% of high-activity sequences from a vast sequence landscape. -
Off-Target Mitigation
Identifies seed-region off-target risks and immunogenicity hotspots, supporting upfront safety design. -
Delivery Assessment
Provides comprehensive delivery solutions including GalNAc and LNP across diverse tissues and organs, such as liver and CNS. -
Dry-Wet Closed Loop
Active learning drives a dry-wet closed loop, reducing blind experimental rounds by over 50%, with daily iterative model updates. -
Patent Positioning
AI-generated de novo sequences supporting differentiated sequence design and intellectual property positioning.